GlassScriptPhysician profile
Michael J Maglione
NPI 1245656222
$6,556.07
in general payments reported to CMS, 2019-2025
28 companies · $2,339 in 2025
The $2,339 reported for 2025 was more than what 97% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $651 · 2022: $1,304 · 2023: $974 · 2024: $1,288 · 2025: $2,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,155 · Travel and Lodging: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,154.60 |
| Travel and Lodging | $446.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,163.30 | 2022-2025 | |
| Medtronic, INC. | $843.36 | 2021-2025 | Signia |
| Regeneron Healthcare Solutions, INC. | $585.50 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $494.18 | 2024-2025 | Descovy, Veklury |
| W. L. Gore & Associates, INC. | $402.18 | 2021-2022 | |
| Amgen INC. | $399.02 | 2024-2025 | Repatha, Krystexxa |
| Teva Pharmaceuticals USA, INC. | $365.44 | 2022-2024 | Austedo Xr |
| Abbvie INC. | $274.87 | 2022-2024 | |
| Abbott Laboratories | $192.93 | 2025 | Freestyle Libre 3 |
| Emd Serono, INC. | $144.55 | 2025 | |
| Hologic Sales and Service, LLC | $131.42 | 2024 | Aptima |
| Convatec INC. | $129.49 | 2022 | |
| Merck Sharp & Dohme LLC | $125.13 | 2025 | Zerbaxa |
| Chiesi USA, INC. | $124.58 | 2021 | |
| Alnylam Pharmaceuticals INC. | $121.81 | 2023 | Amvuttra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $119.34 | 2021 | |
| Novo Nordisk INC | $112.21 | 2022 | |
| Eisai INC. | $112.10 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $110.00 | 2022 | |
| Edwards Lifesciences Corporation | $108.33 | 2022 | |
| Sage Therapeutics, LLC | $105.52 | 2023 | |
| Inspire Medical Systems, INC. | $103.52 | 2024 | Inspire |
| Madrigal Pharmaceuticals | $95.30 | 2025 | Rezdiffra |
| Biogen, INC. | $62.38 | 2023 | |
| Baxter Healthcare | $52.34 | 2021 | |
| Alexion Pharmaceuticals, INC. | $41.70 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $18.95 | 2025 | Caldolor |
| Shionogi INC | $16.62 | 2023 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Maglione listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.